Michael R. Grever MD

Professor of Medicine, Ohio State University

460 W 10th AveColumbus, OH 43210
Phone+1 614-293-7677
Fax+1 614-293-5614

Dr. Grever is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Grever's full profile Already have an account?

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1976 - 1978
UPMC Medical EducationResidency, Internal Medicine, 1971 - 1974
University of Pittsburgh School of MedicineClass of 1971

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 1978 - 2027
MD State Medical License 1991 - 2008
PA State Medical License 1972 - 1976
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
America's Top Doctors Castle Connolly, 2008-2014

Clinical Trials

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2000 Mar 09
COMPLETED
PHASE3
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED
PHASE2
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
UNKNOWN
PHASE2

Publications & Presentations

PubMed

Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.
Anthony G Mansour, Ying Huang, J Phillip Pemberton, Aseel Alsouqi, Adam S Kittai
Leukemia. 2026-08-01
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.
Clive S Zent, Enrico Tiacci, Robert J Kreitman, Tamar Tadmor, Martin S Tallman
Blood. 2026-07-02
A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.
Aseel Alsouqi, Ying Huang, Beth Christian, John Reneau, Seema A Bhat
European Journal of Haematology. 2026-03-01

Abstracts/Posters

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
Michael R. Grever, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Michael R. Grever, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Michael R. Grever, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Challenges In Management Of Hairy Cell Leukemia In 2019
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Grant Support

Phase I Trials Of Anti-Cancer AgentsNational Cancer Institute2003–2012
Pre-Clinical And Clinical Development Of Silvestrol In Chronic LymphocyticNational Cancer Institute2009–2011
Par04-122, Extramural Research Facilities Improvement P*National Center For Research Resources2010
Signal Transduction And Kinase Inhibition In CLLNational Cancer Institute2006–2010
Molecular Studies Of Drug Resistance In Chronic LymphocyNational Cancer Institute2000–2003